Structure Therapeutics Inc. Annual Report - A Deep Dive into 2025

Uncover the latest insights into Structure Therapeutics Inc. (ticker: GPCR) and its performance for the fiscal year ended December 31, 2025. This summary offers retail investors a clear understanding of the company's financial health, strategic advancements, and future outlook, helping you assess its potential for your investment portfolio.

Business Overview: Structure Therapeutics is a clinical-stage biopharmaceutical company that develops innovative oral small molecule medicines for chronic diseases. The company leverages a proprietary structure-based drug design platform to discover and advance novel G-protein coupled receptor (GPCR) modulators. GPCRs are a large family of cell surface receptors that play crucial roles in many bodily functions and are common targets for drug development. In 2025, the company advanced its lead programs in metabolic diseases and other therapeutic areas, aiming to address significant unmet medical needs with convenient oral therapies.

Financial Performance:

• Revenue: The company generated minimal revenue of $0.5 million for the fiscal year ended December 31, 2025, primarily from research grants and collaboration milestones. This reflects its pre-commercial stage and compares to $0.3 million reported in the prior fiscal year.
• Net Loss: Structure Therapeutics reported a net loss of $(150.0) million for 2025, an increase from $(110.0) million in 2024. Accelerated research and development activities, as the company advanced its clinical pipeline, primarily drove this increased loss.
• Research & Development (R&D) Expenses: R&D expenses totaled $120.0 million for 2025, up from $90.0 million in 2024. This represents a significant investment in advancing their clinical pipeline and discovery efforts.
• General and Administrative (G&A) Expenses: G&A expenses rose to $35.0 million for 2025 from $25.0 million in 2024, reflecting higher operational costs associated with being a public company and expanding operations.

Risk Factors: As a clinical-stage biopharmaceutical company, Structure Therapeutics faces inherent risks, including:

• Clinical Trial Uncertainty: Product candidates may not demonstrate sufficient efficacy or an acceptable safety profile in clinical trials, potentially leading to delays, failures, or termination of development.
• Regulatory Approvals: Uncertainty and lengthy processes in obtaining necessary regulatory approvals from agencies such as the FDA are critical for commercialization.
• Intense Competition: Significant competition from established pharmaceutical companies and other biotechnology firms developing similar or alternative treatments.
• Capital Requirements: The ongoing need for substantial additional capital to fund operations, research and development activities, and pipeline development, with no guarantee of future funding.
• Dependence on Key Candidates: The company's success highly depends on the successful development and commercialization of its lead product candidates, particularly GSBR-1290 and ANPA-0073.
• Intellectual Property Protection: Failure to obtain or maintain adequate intellectual property protection for its product candidates and proprietary technology.

Management Discussion and Analysis (MD&A) Highlights: These highlights provide context for the company's financial health and operational results.

• Significant Developments & Milestones in 2025:
  • GSBR-1290 (Oral GLP-1R Agonist): This lead candidate for obesity and Type 2 Diabetes completed a major milestone with its Phase 2a clinical trial. Preliminary data, announced in Q4 2025, showed promising efficacy in weight loss and glycemic control, along with a favorable safety and tolerability profile. The company began preparing for a pivotal Phase 2b study, slated to commence in Q2 2026.
  • ANPA-0073 (Oral Apelin Receptor Agonist): This program, targeting heart failure, advanced into Phase 1 clinical trials in mid-2025, marking its first human dosing. The company anticipates initial safety data in late 2026.
  • Preclinical Pipeline: The company continued to advance several preclinical candidates. One new program, targeting inflammatory diseases, is expected to enter IND-enabling studies in early 2026. (IND-enabling studies are the final non-clinical tests required before submitting an Investigational New Drug application to begin human trials).
  • Intellectual Property: The company strengthened its intellectual property portfolio, securing several new patents for its lead compounds and proprietary platform technology.
• Liquidity and Capital Resources: A successful capital raise significantly bolstered the company's financial position, providing funds for continued operations and pipeline advancement. The higher net loss and R&D expenses reflect the company's strategic investment in its clinical programs.

Financial Health:

• Cash Position: The company held $400.0 million in cash, cash equivalents, and marketable securities as of December 31, 2025. This provides an estimated 2.5-year cash runway based on current spending.
• Capital Raise: In Q3 2025, Structure Therapeutics successfully completed a follow-on public offering, raising $200.0 million in net proceeds to fund ongoing clinical trials and pipeline expansion.
• Debt: The company had no outstanding debt as of December 31, 2025, relying primarily on equity financing for operations.
• Liquidity: The company believes its current cash, cash equivalents, marketable securities, and recent capital raise proceeds will fund operating expenses and capital expenditures for at least the next 24 months.

Future Outlook: Looking ahead, Structure Therapeutics focuses on:

• Initiating and enrolling patients in the Phase 2b clinical trial for GSBR-1290.
• Reporting initial Phase 1 data for ANPA-0073.
• Advancing its preclinical pipeline, aiming to file at least one Investigational New Drug (IND) application for a new candidate. (An IND application is a request to the FDA to begin human clinical trials).
• Continuing to explore strategic partnerships to maximize the value of its platform and pipeline. The company anticipates that its operating expenses will continue to increase as it advances product candidates through clinical development, expands research and development activities, and incurs additional costs associated with being a public company.

Competitive Position: Structure Therapeutics navigates highly competitive and rapidly evolving therapeutic areas. Its proprietary structure-based drug design platform drives the company's competitive position, enabling the development of differentiated oral small molecule GPCR modulators. Key aspects of its competitive strategy include:

• Differentiation: Develop oral therapies for diseases currently treated by injectables or with limited oral options, offering potential advantages in patient convenience and adherence.
• Scientific Expertise: Leverage its deep understanding of GPCR biology and structure-based drug design to create novel compounds with improved selectivity, potency, and pharmacokinetic profiles.
• Intellectual Property: Continuously strengthen its intellectual property portfolio to protect product candidates and platform technology, creating barriers to entry for competitors.
• Clinical Development: Execute efficient and robust clinical development programs to demonstrate superior efficacy and safety profiles for its lead candidates.

The company competes with large pharmaceutical companies, established biotechnology companies, and academic institutions developing or having developed products for similar indications. Many of these competitors possess significantly greater financial, technical, and human resources. The company's ability to successfully compete will depend on its capacity to develop and commercialize product candidates superior in efficacy, safety, convenience, or cost.

Company Standing & Market Data:

• Public Company Status: The SEC designates Structure Therapeutics as a "Large Accelerated Filer" and a "Well-Known Seasoned Issuer." This means it is an established public company with a market capitalization exceeding $700 million. Such a designation subjects the company to robust reporting requirements and makes it eligible for streamlined registration processes, signaling maturity and transparency in its financial disclosures.
• Market Capitalization: The company's market valuation stood at approximately $834.9 million as of June 30, 2025.
• Shares Outstanding: Approximately 212.5 million ordinary shares were outstanding as of February 15, 2026. Most of these shares trade as American Depositary Shares (ADSs) on the Nasdaq Global Market under the ticker symbol GPCR. Each ADS represents a specific number of ordinary shares, simplifying trading for U.S. investors.